Inogen, Inc (NASDAQ:INGN)‘s stock had its “hold” rating reiterated by Piper Jaffray Companies in a research report issued on Tuesday. They currently have a $90.00 price target on the medical technology company’s stock. Piper Jaffray Companies’ price objective would suggest a potential downside of 13.87% from the company’s previous close.
A number of other analysts also recently commented on the stock. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “strong-buy” rating and set a $94.00 price target on the stock in a research report on Monday, May 15th. Needham & Company LLC dropped their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research report on Thursday, June 8th. J P Morgan Chase & Co boosted their price target on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research report on Monday, June 26th. Finally, BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research report on Monday, July 31st. Four equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $91.33.
Shares of Inogen (NASDAQ:INGN) traded up 0.12% on Tuesday, reaching $104.49. 110,909 shares of the company’s stock traded hands. The company has a 50 day moving average price of $94.81 and a 200 day moving average price of $86.53. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 90.70 and a beta of 1.02. Inogen has a 52 week low of $50.24 and a 52 week high of $104.88.
Inogen (NASDAQ:INGN) last released its quarterly earnings results on Thursday, August 3rd. The medical technology company reported $0.38 EPS for the quarter, topping analysts’ consensus estimates of $0.28 by $0.10. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company had revenue of $64.10 million for the quarter, compared to the consensus estimate of $59.99 million. During the same period in the previous year, the firm earned $0.25 EPS. Inogen’s revenue was up 17.4% on a year-over-year basis. On average, equities research analysts predict that Inogen will post $1.21 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Inogen, Inc (INGN) Given “Hold” Rating at Piper Jaffray Companies” was reported by Stock Observer and is the property of of Stock Observer. If you are reading this story on another publication, it was stolen and republished in violation of international copyright legislation. The correct version of this story can be viewed at https://www.thestockobserver.com/2017/09/12/inogen-inc-ingn-given-hold-rating-at-piper-jaffray-companies.html.
In related news, Director Raymond Huggenberger sold 15,300 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $90.88, for a total transaction of $1,390,464.00. Following the transaction, the director now owns 7,808 shares of the company’s stock, valued at $709,591.04. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Alison Bauerlein sold 6,667 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was sold at an average price of $92.64, for a total transaction of $617,630.88. Following the transaction, the executive vice president now directly owns 15,000 shares in the company, valued at approximately $1,389,600. The disclosure for this sale can be found here. Insiders sold a total of 59,967 shares of company stock worth $5,532,015 in the last ninety days. Corporate insiders own 5.31% of the company’s stock.
A number of hedge funds have recently made changes to their positions in the stock. BlackRock Inc. increased its position in Inogen by 1.9% during the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock worth $205,207,000 after acquiring an additional 39,752 shares during the period. Vanguard Group Inc. increased its holdings in Inogen by 24.9% in the 2nd quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after buying an additional 301,737 shares during the period. Blair William & Co. IL increased its holdings in Inogen by 1.9% in the 1st quarter. Blair William & Co. IL now owns 921,693 shares of the medical technology company’s stock valued at $63,462,000 after buying an additional 17,377 shares during the period. Koch Industries Inc. increased its holdings in Inogen by 19,485.8% in the 2nd quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after buying an additional 653,747 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in Inogen by 3.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after buying an additional 17,111 shares during the period.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.